Background Prostate cancer is a heterogeneous disease, but current treatments are not based
on molecular stratification. We hypothesized that metastatic, castration-resistant prostate …

This document is a summary statement of the outcome from the meeting:“Bisphenol A: An
Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for …

Retinoblastoma (RB; encoded by RB1) is a tumor suppressor that is frequently disrupted in
tumorigenesis and acts in multiple cell types to suppress cell cycle progression. The role of …

The androgen receptor (AR) is a critical effector of prostate cancer development and
progression. The dependence of this tumor type on AR activity is exploited in treatment of …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole-genome …

Clinical data and models of human disease indicate that androgen receptor (AR) activity is
essential for prostate cancer development, growth, and progression. The dependence of …

While mutations affecting protein-coding regions have been examined across many cancers,
structural variants at the genome-wide level are still poorly defined. Through integrative …

Two decades after the discovery of the first animal microRNA (miRNA), the number of miRNAs
in animal genomes remains a vexing question. Here, we report findings from analyzing …

The retinoblastoma tumour suppressor (RB) is a crucial regulator of cell-cycle progression
that is invoked in response to a myriad of anti-mitogenic signals. It has been hypothesized that …

PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation.
PARP-1 has well-described functions in DNA damage repair and also functions as a …